Microcap Ledger Serina Therapeutics, Inc. $SER
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Pharmaceutical Preparations
- Headquarters
- Huntsville, AL
- Fiscal year end
- December 31
- Shares outstanding
- 25,400,473 [10-Q 2026-08-13]
What the company doesAI summary of filing
Serina Therapeutics is a clinical-stage biotechnology company developing drug product candidates using its proprietary POZ (poly(2-oxazoline)) polymer technology, designed to modify existing and novel drugs to improve efficacy and safety profiles. The company focuses on neurological diseases, particularly Parkinson's disease, with its lead candidate SER 252 (POZ-apomorphine) in Phase 1 clinical trials for advanced Parkinson's disease treatment. The company generates revenue through licensing agreements, including a non-exclusive license with Pfizer involving upfront payments, milestone payments, and tiered royalties on net sales. Serina is pre-revenue from product sales and has a history of operating losses expected to continue. [10-K 2026-03-25]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$13.25M | −$11.25M | $23.02M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $130.0K | −$19.18M | −$17.95M | $3.06M | [10-K 2026-03-25] |
| FY ended Dec 2024 | $56.0K | −$11.14M | −$17.14M | $3.67M | [10-K 2026-03-25] |
- Quarterly cash burn
- −$5.63M
- Cash runway Estimate
- ~12.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-07 | 8,891,976 | [10-Q 2024-11-12] |
| 2025-03-20 | 9,932,215 | [10-K 2025-03-24] |
| 2025-05-06 | 9,967,381 | [10-Q 2025-05-08] |
| 2025-08-08 | 10,250,588 | [10-Q 2025-08-11] |
| 2025-11-10 | 10,664,064 | [10-Q 2025-11-13] |
| 2026-03-18 | 12,314,159 | [10-K/A 2026-03-27] |
| 2026-05-10 | 14,997,505 | [10-Q 2026-05-14] |
| 2026-08-10 | 25,400,473 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-08-24; declared effective 2026-08-31 [S-1 2026-08-24]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-01-15. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-01-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-01-15] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-07 | Brannan Stephen K. | buy | 1,000 | $2.03 | [4 2026-07-09] |
| 2026-06-17 | Venkatesan Jay | other | 224,152 | $2.25 | [4 2026-06-22] |
| 2026-06-17 | Bailey Gregory | other | 1,770,805 | $2.25 | [4 2026-06-22] |
| 2026-06-17 | Bailey Gregory | other | 6,666,667 | $2.25 | [4 2026-06-22] |
| 2026-06-12 | Wilson Karen J | buy | 5,000 | $1.77 | [4 2026-06-15] |
| 2026-06-11 | Wilson Karen J | buy | 5,100 | $1.75 | [4 2026-06-15] |
| 2026-05-22 | Venkatesan Jay | buy | 589 | $1.78 | [4 2026-06-22] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Charter, bylaws or fiscal year change |
| 2026-09-09 | 8-K | Other events |
| 2026-08-27 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-08-24 | S-1 | Registration statement |
| 2026-08-13 | 8-K | Results of operations |
| 2026-08-13 | 10-Q | Quarterly report |
| 2026-07-23 | 8-K | Director or officer change |
| 2026-07-22 | 8-K | Director or officer change |
| 2026-07-22 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-06-24 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-05-22 | S-3 | Registration statement |
| 2026-05-14 | 8-K | Results of operations |
Alerts for $SER
Email me when Serina Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.